Artelo Biosciences Announces Reverse Stock Split
Rhea-AI Summary
Artelo Biosciences (Nasdaq: ARTL) announced a 3-for-1 reverse stock split approved by the board on February 27, 2026. The split will combine every three outstanding shares into one and will be effective for trading on a split-adjusted basis at the open on March 10, 2026.
The company said the Board adopted the 3-for-1 ratio to increase the per-share price to improve marketability and liquidity. The new CUSIP after the reverse split will be 04301G706, and there will be approximately 708,258 shares issued and outstanding immediately after the split. All outstanding warrants and derivatives will automatically adjust per their terms.
Positive
- Board approved a 3-for-1 reverse split on February 27, 2026
- Shares to trade on a split-adjusted basis starting March 10, 2026
- New CUSIP 04301G706 assigned after the reverse split
- Outstanding warrants and derivatives will automatically adjust
Negative
- Total issued and outstanding shares reduced to ~708,258 after the split
- Reverse split is a capital action that may change per-share metrics immediately
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves: SILO and CERO are up, while TNFA, ADIL, and HCWB are down. Momentum scanner only flagged NCNA up 10.71%, suggesting ARTL’s reverse split is a stock-specific event rather than a coordinated biotech move.
Previous Stock split Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 11 | Reverse stock split | Neutral | +6.2% | Announced 6-for-1 reverse split to meet Nasdaq bid price requirement. |
Prior reverse split news in June 2025 was followed by a positive +6.19% reaction, indicating the stock has previously traded higher around similar corporate actions despite listing and liquidity pressures elsewhere in filings.
Over the past six months, Artelo has combined clinical updates with significant capital structure and listing developments. In June 2025, a 6-for-1 reverse split reduced outstanding shares to about 546,667, with a +6.19% next-day move. Subsequent filings highlighted going-concern risks, multiple financings, and a Nasdaq delisting determination. Today’s 3-for-1 reverse split continues this pattern of using share structure changes while maintaining pro‑rata ownership and adjusting existing derivatives.
Historical Comparison
In the past year, ARTL disclosed one reverse split (6-for-1 in June 2025) that saw a +6.19% next-day move. The current 3-for-1 reverse split follows the same pattern of adjusting share count while keeping pro‑rata ownership unchanged.
Artelo has now executed sequential reverse stock splits (6-for-1 in 2025, 3-for-1 in 2026), each reducing outstanding shares while maintaining proportional ownership and adjusting warrants and derivatives under existing terms.
Market Pulse Summary
This announcement details a 3-for-1 reverse stock split effective on March 10, 2026, reducing outstanding shares to about 708,258 while preserving each holder’s pro‑rata ownership and adjusting existing warrants and derivatives. In context of earlier SEC filings highlighting going‑concern risk and Nasdaq listing challenges, investors may focus on how this structural change interacts with future capital raises, resale activity, and the company’s ability to execute on its clinical programs.
Key Terms
reverse stock split financial
cusip financial
warrants financial
AI-generated analysis. Not financial advice.
Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026
SOLANA BEACH, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced that on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”). The Company’s common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, March 10, 2026. The Board of Directors determined the 3-for-1 ratio to be appropriate in order to increase the price per share of the Common Stock to improve its marketability and liquidity. The new CUSIP number for the Common Stock following the Reverse Split will be 04301G706.
As a result of the Reverse Split, each three shares of the Company’s issued and outstanding Common Stock will be automatically combined and converted into one issued and outstanding share of Common Stock. No fractional shares will be issued as a result of the Reverse Split. Stockholders who otherwise would be entitled to a fractional share because they hold a number of shares not evenly divisible by the 3-for-1 ratio will automatically be entitled to receive one whole share of Common Stock for each such fractional share. Each shareholder’s pro-rata percentage ownership will remain unchanged as a result of the reverse split and no further action is required by shareholders. All of the Company’s current outstanding warrants to purchase shares of Common Stock and other derivatives automatically adjust per their terms to reflect the reverse split. Immediately after the reverse split becomes effective, there will be approximately 708,258 shares of Common Stock issued and outstanding. For further details, all shareholders are invited to review the 8-K regarding this reverse split which will be filed March 6, 2026.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices, including digital assets, to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
What is the reverse stock split for Artelo Biosciences (ARTL) and when was it approved?
When will ARTL shares begin trading on a split-adjusted basis?
How many Artelo shares will be outstanding after the reverse split (ARTL)?
Will fractional shares be issued following Artelo's (ARTL) 3-for-1 reverse split?
What happens to Artelo's (ARTL) warrants and derivatives after the reverse split?
